obesity-weight-loss-summit.com
Open in
urlscan Pro
5.134.13.35
Public Scan
URL:
https://obesity-weight-loss-summit.com/
Submission: On January 10 via api from US — Scanned from US
Submission: On January 10 via api from US — Scanned from US
Form analysis 1 forms found in the DOM
GET https://obesity-weight-loss-summit.com/
<form role="search" method="get" id="searchform" class="searchform" action="https://obesity-weight-loss-summit.com/">
<div>
<label class="screen-reader-text" for="s"> Search</label>
<input type="text" value="" name="s" id="s" placeholder="">
<input type="submit" id="searchsubmit" value="Search">
</div>
</form>Text Content
Skip to content RAN MAY 31 - JUNE 1, 2023 BOSTON, MA REGISTER INTEREST FOR 2024 YOUR NEXT MEETING IN THE SERIES: 7TH OBESITY & NASH SUMMIT (NOVEMBER 2023) Menu * Home * About * About Event * Hanson Wade * What’s On? * 2023 Full Event Guide * 2023 Speakers * Partner * Partnership Opportunities * 2023 Partners * Take Part * Register Interest * Contact Us * Home * About * About Event * Hanson Wade * What’s On? * 2023 Full Event Guide * 2023 Speakers * Partner * Partnership Opportunities * 2023 Partners * Take Part * Register Interest * Contact Us RAN 30 MAY - 1 JUNE, 2023 BOSTON, MA THANK YOU TO OUR SPEAKERS, SPONSORS, AND DELEGATES WHO JOINED US AT THE NOVEL THERAPIES FOR TYPE 2 DIABETES & OBESITY SUMMIT! IF YOU ARE INTERESTED IN THE 2024 EVENT, PLEASE GET IN TOUCH AT INFO@HANSONWADE.COM OR BY USING THE BUTTON BELOW: REGISTER INTEREST SEE OUR OTHER EVENTS IN THIS SERIES: 2023 EVENT GUIDE ABOUT PARTNERING THE 2023 NOVEL THERAPIES FOR TYPE 2 DIABETES AND OBESITY SUMMIT Advanced GLP-1 Receptor Agonists & Novel Therapies to Rival Bariatric Surgery Identified Disease-Modifying Targets to Sustainably Transform Glycaemic Control Managed Diabetic Complications to Reduce Mortality in Metabolic Disorders The wave of breakthrough therapies in drug-based management of obesity has triggered a renaissance in metabolic disorders. As GLP-1 receptor agonists establish a new gold standard in weight-loss and first-in-class therapies demonstrate additional benefit in type 2 diabetes, stakeholders are flooding in to redefine the metabolic landscape. We united industry experts that were dedicated to accelerating the frontier of disease-modifying therapeutics beyond the current standard of care. The Novel Therapies for Type 2 Diabetes & Obesity Summit was the definitive industry forum, sharing cross-industry insights to treat an exponentially growing patient population. From elucidating body weight set points to establishing opportunities for therapeutic intervention, to demonstrating metabolic effect in diabetes to treat interrelated cardiorenal comorbidities, we joined industry experts including Novo Nordisk, Eli Lilly & Company, Altimmune, Regeneron, Boehringer Ingelheim, Amgen and more and navigated the pathway to regulatory approval for big pharma and smaller biotech. THE 2023 WORLD-CLASS SPEAKER FACULTY INCLUDES: JYOTHIS GEORGE Vice President - Global Medical General Medicine Amgen KIEREN MATHER Associate Vice President, Medical Diabetes & Incretin Early Clinical Research Eli Lilly & Co. MIRIAM KIDRON Chief Scientific Officer Oramed Pharmaceuticals NANCY BRIEFS Co-Founder, President & Chief Executive Officer AltrixBio OFRI MOSENZON Senior Medical Director Regeneron Pharmaceuticals Inc ULI STILZ Vice President, Head of Bio Innovation Hub Novo Nordisk VIEW 2023 SPEAKERS “This meeting allows for dialogue and collaboration between groups that all want the same thing: eradicate the greatest threats to metabolic health in the modern age.” Siddique Abbasi, Executive Medical Director & Global Development Lead, Amgen “An opportunity to engage in a robust scientific discussion with the companies leading the way towards effective therapeutic strategies for obesity and related metabolic diseases.” Randy Seeley, Henry King Ransom Professor of Surgery, University of Michigan “These meetings bring together stakeholders from multiple backgrounds allowing the type of interactions that are needed for researchers, drug developers, and policy makers to establish and develop new pathways to improve healthcare.” Jerry Colca, Chief Scientific Officer, Cirius Therapeutics OTHER EVENTS IN THE SERIES OUR CONTACT DETAILS Phone UK: +44 (0)20 3141 8700 US: +1 617 455 4188 Email info@hansonwade.com JOIN OUR TEAM We are always looking for ambitious people to join our team. You'll have opportunities to learn quickly, advance your career, and to meaningfully impact our customers and our business. Click here to learn about careers. ABOUT US Hanson Wade specializes in scientific research across a comprehensive range of distinctive R&D areas. We deliver insight and connections to facilitate safe and effective drug development for more personalized and targeted patient populations. EXPLORE OUR PRODUCTS Conferences Beacon Searchlight Intelligence SEARCH Search ORGANIZED BY Terms & Conditions Privacy Policy A Hanson Wade Group Company © Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216. Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH. We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok